Literature DB >> 12439915

Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori -associated gastric diseases.

Dong-Li Guo1, Ming Dong, Lan Wang, Li-Ping Sun, Yuan Yuan.   

Abstract

AIM: To investigate the relationship between the antigen MG7 antigen expression and gastric cancer as well as precancerous condition; to study the relationship between the MG7 antigen expression and H. pylori infection in benign gastric lesions in order to find out the effect of H. pylori infection on the process of gastric cancer development.
METHODS: The level of MG7 antigen expression was determined by immunohistochemical method in 383 gastric biopsied materials. The intestinal metaplasia was determined by histochemistry method. The H. pylori infection was determined by HE stain, PCR and ELISA in 291 specimens, among which only 34 cases of H. pylori-associated gastric lesions were followed up.
RESULTS: The positive rate of MG7 expression in normal gastric mucosa, intestinal metaplasia, dysplasia and gastric cancer increased gradually in ascending order (P<0.01). The positive rate of MG7 antigen expression in type III intestinal metaplasia of gastric mucosa was higher than that of type I and II intestinal metaplasia, being highly significant (P<0.05).The positive rate of MG7 antigen expression in superficial gastritis, atrophic gastritis and gastric cancer increased gradually (11.9 %, 64.8 %, 91.2 %, P<0.01). There was no significant difference between H. pylori-negative and H. pylori-positive intestinal metaplasia, atrophic gastritis and dysplasia of gastric epithelium in the positive rate of MG7 antigen expression. There was no expression of MG7 antigen in H. pylori-negative superficial gastritis. The positive rate of MG7 expression in H. pylori-positive superficial gastritis was 20.5 %, and the difference between them was significant (P<0.05). During following up, one of the three H. pylori negative cases turned positive again, and its MG7 antigen expression turned to be stronger correspondingly. 3 of 31 H. pylori positive cases were detected as early gastric cancer, among which one with "+++" MG7 antigen expression was diminished after H. pylori eradication.
CONCLUSION: MG7 antigen expression is highly specific in gastric cancer and can be used as a good marker for screening of gastric cancer; type III intestinal metaplasia, atrophic gastritis and dysplasia should be followed up and MG7 antigen expression has high clinical value in the dynamic follow-up study; although the positive -MG7 in positive -H. pylori superficial gastritis show benign morphology in features, there is still the potential risk of developing into gastric cancer, hence special attention should be paid to those showing increasing MG7 antigen expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439915      PMCID: PMC4656370          DOI: 10.3748/wjg.v8.i6.1009

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  [Effect of Helicobacter pylori on gastric epithelial apoptosis].

Authors:  Q Dong; W Liu; X Zheng
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1997-11

2.  Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique.

Authors:  J Ren; Z Chen; S J Juan; X Y Yong; B R Pan; D M Fan
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

3.  Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation.

Authors:  D Forman; D G Newell; F Fullerton; J W Yarnell; A R Stacey; N Wald; F Sitas
Journal:  BMJ       Date:  1991-06-01

4.  Helicobacter pylori membrane protein 1: a new carcinogenic factor of Helicobacter pylori.

Authors:  M Suganuma; M Kurusu; S Okabe; N Sueoka; M Yoshida; Y Wakatsuki; H Fujiki
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

5.  Apoptosis, proliferation and p53 gene expression of H. pylori associated gastric epithelial lesions.

Authors:  Z Zhang; Y Yuan; H Gao; M Dong; L Wang; Y H Gong
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

6.  Overexpression of cyclin E in Mongolian gerbil with Helicobacter pylori-induced gastric precancerosis.

Authors:  Yong-Li Yao; Bo Xu; Yu-Gang Song; Wan-Dai Zhang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

7.  Possible role of Helicobacter pylori infection in early gastric cancer development.

Authors:  M Asaka; T Kimura; M Kato; M Kudo; K Miki; K Ogoshi; T Kato; M Tatsuta; D Y Graham
Journal:  Cancer       Date:  1994-06-01       Impact factor: 6.860

8.  [The expression of MG7 corresponding antigen in gastrointestinal polyps and its relation with cancer].

Authors:  S Z Chen
Journal:  Zhonghua Wai Ke Za Zhi       Date:  1992-12

9.  Subtypes of intestinal metaplasia and gastric carcinoma. A clinicoendoscopic follow-up of 112 cases.

Authors:  D C Fang; W W Liu
Journal:  Chin Med J (Engl)       Date:  1991-06       Impact factor: 2.628

10.  Gastric cancer risk in relation to Helicobacter pylori infection and subtypes of intestinal metaplasia.

Authors:  M S Wu; C T Shun; W C Lee; C J Chen; H P Wang; W J Lee; J T Lin
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

View more
  21 in total

1.  Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.

Authors:  Xiao-Dong Wang; Ning-Ning Gao; Yu-Wen Diao; Yu Liu; Dong Gao; Wang Li; Yan-Yan Wan; Jing-Jing Zhong; Guang-Yi Jin
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

Review 2.  Gastric cancer and the epoch of immunotherapy approaches.

Authors:  Elena Niccolai; Antonio Taddei; Domenico Prisco; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

3.  Screening and identification of mimotope of gastric cancer associated antigen MGb1-Ag.

Authors:  Zhe-Yi Han; Kai-Chun Wu; Feng-Tian He; Quan-Li Han; Yong-Zhan Nie; Ying Han; Xiao-Nan Liu; Jian-Yong Zheng; Mei-Hong Xu; Tao Lin; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

4.  Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer.

Authors:  Qiang Tong; Ke Liu; Xiao-Ming Lu; Xiao-Gang Shu; Guo-Bin Wang
Journal:  J Biomed Biotechnol       Date:  2010-03-22

5.  Construction of expression systems for flaA and flaB genes of Helicobacter pylori and determination of immunoreactivity and antigenicity of recombinant proteins.

Authors:  Jie Yan; Shao-Hui Liang; Ya-Fei Mao; Li-Wei Li; Shu-Ping Li
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

6.  Construction of hpaA gene from a clinical isolate of Helicobacter pylori and identification of fusion protein.

Authors:  Ya-Fei Mao; Jie Yan; Li-Wei Li; Shu-Ping Li
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

7.  Construction of prokaryotic expression system of ureB gene from a clinical Helicobacter pylori strain and identification of the recombinant protein immunity.

Authors:  Ya-Fei Mao; Jie Yan
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

8.  Construction of a prokaryotic expression system of vacA gene and detection of vacA gene, VacA protein in Helicobacter pylori isolates and ant-VacA antibody in patients' sera.

Authors:  Jie Yan; Ya-Fei Mao
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

9.  Construction of prokaryotic expression system of 2 148-bp fragment from cagA gene and detection of cagA gene, CagA protein in Helicobacter pylori isolates and its antibody in sera of patients.

Authors:  Jie Yan; Yuan Wang; Shi-He Shao; Ya-Fei Mao; Hua-Wen Li; Yi-Hui Luo
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

10.  Establishment of Helicobacter pylori infection model in Mongolian gerbils.

Authors:  Jie Yan; Yi-Hui Luo; Ya-Fei Mao
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.